What GHK-Cu is
GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It is studied mainly in cell, animal, cosmetic, and small topical human studies. Mechanistic findings about collagen, extracellular-matrix remodeling, or gene expression do not establish that an injected or topical commercial product produces a clinical benefit.
Route is central: topical skin exposure, application to a treated wound, and systemic injection are not equivalent. The evidence and risks for one route cannot be transferred to another.
Topical human evidence is limited and mixed
In a randomized study after carbon-dioxide laser resurfacing, only 13 patients completed follow-up. Objective computer and blinded assessments found no significant advantage for GHK-Cu in redness resolution, wrinkles, or overall skin quality, although patient-reported satisfaction favored the GHK-Cu regimen.[1]
A 45-person hair-loss study tested a combination of 5-aminolevulinic acid plus GHK—not GHK-Cu alone—and reported improved hair counts in some groups but no significant differences in length or thickness.[2] It cannot isolate the contribution of GHK or support injectable use. Broad claims about wound healing, hair restoration, whole-body repair, or anti-aging exceed this evidence.
Injectable claims lack a human evidence base
No FDA-approved injectable GHK-Cu drug or established human injection regimen was identified. FDA states that compounded injectable GHK-Cu may pose immunogenicity risks because of aggregation and peptide-related impurities, and that human data are limited for safety assessment.[3]
Topical cosmetic experience cannot establish systemic safety, sterility, pharmacokinetics, organ exposure, or a dose-response relationship for injection.
Current compounding status is not approval
As of May 2026, FDA’s 503A category document lists GHK-Cu for non-injectable routes as a nominated substance under evaluation and says the agency intends to consult its compounding advisory committee before the end of February 2027.[4] Category 1 is an interim enforcement-policy category—not a finding that the substance is safe, effective, or FDA-approved.
Injectable GHK-Cu is separately identified in FDA safety materials. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[5]
What can be concluded
GHK-Cu has biological plausibility and limited topical human data, but no reliable evidence for systemic anti-aging, injury recovery, muscle growth, or injectable benefit. Teloryx therefore grades the evidence C for narrow topical questions and withholds every injection, dose, reconstitution, and cycling protocol.